Hoth Therapeutics

Hoth Therapeutics to Pursue Expanded Access for HT-001 to Treat EGFR Inhibitor-Related Skin Toxicities

2 months ago

• Hoth Therapeutics plans to submit an Expanded Access application for HT-001, a novel therapy targeting dermatological side effects in cancer patients receiving EGFR inhibitor treatments. • The "compassionate use" program would allow eligible patients with serious conditions to access HT-001 outside of clinical trials while the company continues to gather safety and efficacy data. • Positive progress in ongoing clinical studies has prompted this initiative, which aims to address a significant unmet need affecting quality of life for cancer patients undergoing targeted therapies.

Hoth Therapeutics' HT-KIT Shows Promising Results Against Gastrointestinal Stromal Tumors in Preclinical Study

2 months ago

• Hoth Therapeutics' novel therapy HT-KIT demonstrated significant efficacy in reducing KIT receptor expression and inducing tumor cell death within 24 hours in preclinical GIST models. • The treatment led to marked tumor volume reduction in humanized xenograft models, with statistically significant differences emerging by day 8 and continuing to increase over time. • HT-KIT represents a potential breakthrough for GIST patients facing treatment resistance to current tyrosine kinase inhibitors by directly targeting the underlying KIT mutations driving cancer progression.

Hoth Therapeutics Addresses Market Rumors and Advances HT-001 Clinical Trial

4 months ago

• Hoth Therapeutics has confirmed it is not planning any public or private offering, maintaining a strong financial position with over $10 million in cash and no debt. • The company's lead therapeutic candidate, HT-001, is currently in clinical development for treating rash and skin disorders associated with cancer therapy. • Enrollment in the HT-001 clinical trial is progressing as planned, with all trial sites now active and enrolling participants, marking a significant milestone. • Hoth Therapeutics reaffirms its commitment to transparency and will continue to provide updates on material developments, focusing on long-term value creation.

Hoth Therapeutics' HT-001 Demonstrates 100% Success in Phase 2a Trial for Cancer Treatment Skin Toxicities

5 months ago

• Hoth Therapeutics' HT-001 achieved a 100% success rate in a Phase 2a trial, significantly improving skin toxicities caused by EGFR inhibitors in cancer patients. • The CLEER-001 trial data showed that all patients achieved the primary efficacy endpoint, with notable improvements in skin toxicity by the six-week mark. • 66% of patients reported reduced pain and itching, enhancing their quality of life, while maintaining their full cancer treatment dosage without interruptions. • HT-001 exhibits a strong safety profile with no treatment-related adverse effects, suggesting its potential as a new standard of care in this area.

Hoth Therapeutics Receives US Patent for HT-ALZ, a Novel Alzheimer's Treatment

7 months ago

• Hoth Therapeutics has been granted a U.S. patent for HT-ALZ, a novel therapy targeting the Substance P/Neurokinin-1 Receptor pathway for Alzheimer's disease. • Preclinical studies of HT-ALZ have demonstrated reduced neuroinflammation and improved cognitive functions, marking a potential breakthrough in Alzheimer's treatment. • The company is advancing HT-ALZ towards clinical trials, with formulation underway to assess safety, tolerability, and efficacy in slowing cognitive decline. • HT-ALZ differentiates itself by focusing on neuroinflammation, offering a new approach compared to treatments primarily targeting amyloid plaques.

Hoth Therapeutics' HT-001 Shows Promise in Treating EGFRI-Associated Skin Toxicities

9 months ago

• Hoth Therapeutics reports positive data from a human case study using HT-001 to treat EGFR inhibitor-associated papulopustular eruptions (PPEs). • A metastatic breast cancer patient experienced rapid symptom improvement after one week of HT-001 treatment, leading to treatment cessation. • The patient showed no new lesion development in the three weeks following treatment, suggesting HT-001's potential efficacy and safety. • A Phase 2a clinical trial is underway to further evaluate HT-001's efficacy and safety in managing EGFRI-associated skin toxicities.